
1	
2	
3	<u>Case study</u>
4	A Late Presenting Urachal Remnant Tumour:
5	
6	Rare Adenocarcinoma Originated from
7	Developmental Defect
8	
9	ABSTRACT
10	ADSTRACT
11	Occupying only 0.01% of all adult concernations, the rare
12	Occupying only 0.01% of all adult cancer patients, the rare
13	entity urachal adenocarcinoma constitutes 22-35% of adenocarcinomas originating from urinary bladder. Though
14	
15	with the gradual descend of the bladder in the course of development urachus should turn into median umbilical
16	ligament, exceptional persistence of it can give rise to urachal
17 18	cyst or urachal adenocarcinoma in adulthood. With only 43%
18 19	of survival rate for 5 years and mean survival between 12 and
19 20	24 months urachal carcinoma is a devastating disease.
20 21	Diagnosis of it is based on the MD Anderson Cancer Centre
	(MDACC) criteria. Computed Tomography (CT) Scan and/or
22	Magnetic Resonance Imaging (MRI) Scan of abdomen and
23	pelvis are the major imaging modalities to proceed towards
24 25	diagnosis and staging. Not only histopathological examination
	but also immune-histochemical expression of both CK7 and
26 27	CK20 suffice to clinch the diagnosis. Though surgical
27 28	intervention forms the mainstay of treatment, several
28 29	regimens of chemotherapy have also been tried to fight
	against unresectable, residual, extensive urachal carcinomas.
30 31	against unresociable, residuar, extensive uracitar caremonias.
31 32	This case took place in a 52 years old male patient who was
32 33	presented with a gradually enhancing infra-umbilical swelling
	with slow growing urinary symptoms. By dint of
34	with slow growing urmary symptoms. By unit of

Ultrasonography(USG) and Contrast Enhanced CT(CECT) 35 scan of whole abdomen the tumour was detected involving the 36 bladder wall and the anterior abdominal wall. Cystoscopy was 37 followed by upfront cytoreductive surgery. Histopathological 38 examination revealed the diagnosis of an adenocarcinoma 39 which was further confirmed to be an urachal remnant 40 carcinoma with the help of immunohistochemistry. Post-41 operative CT scan showed residual disease involving bladder 42 wall and was treated with an adjuvant platin based 43 chemotherapy regimen. 44 45 46 **INTRODUCTION** 47 48 49 Urachal remnant tumour comprising 0.35 to 0.7% of all 50 bladder malignancies is a rare entity [1]. We report a case of 51 urachal adenocarcinoma treated with combined modalities, 52 i.e. surgery followed by adjuvant chemotherapy. As 'rare 53 diagnosis is rarely right', this case was even thought to be an 54 adenocarcinoma of colonic origin with clinical and 55 radiological resemblance with urachal remnant tumour. 56 However, in spite of the confusing radiological features of the 57 tumour the diagnosis was finally clinched on the basis of 58 immunohistochemistry and treated accordingly to achieve a 59 relatively prolonged disease free survival (DFS). 60 61 62 CASE REPORT 63 64 A 52 years old male patient, hypertensive, euglycaemic with 65 past medical history of pulmonary tuberculosis in 1985, 66 without any significant family history first attended the out 67 patient department on with chief complaints of urinary 68

urgency and lower backache for last 15 days. While the 69 present history of illness was cultivated, difficulty in 70 micturition for last 6 months and gradually enhancing infra-71 umbilical swelling for last 5 months came in scene. On 72 investigation, blood parameters including serum urea and 73 serum creatinine were within normal limit. Serum Prostate 74 Specific Antigen (PSA) was 1.03 ng/ml performed in the 75 week of presentation which excluded prostatic pathology too. 76 Ultrasonography of whole abdomen done on the same day 77 revealed a 6.6 cm X 5.8 cm heterogeneous hypoechoic space 78 occupying lesion (SOL) involving the anterior abdominal wall 79 connected to urinary bladder which first evoked the suspicion 80 for urachal remnant tumour. Subsequently, a Contrast 81 Enhanced Computed Tomography (CECT) scan of whole 82 abdomen was done within one week which clearly showed a 83 septate cystic SOL measuring 5.8cm X 4cm in umbilical area 84 attached to urinary bladder wall (Figure 1 & 2). 85 86







- 95
- ⁹⁶ Figure 2: Sagittal view in CECT scan shows SOL originated
- ⁹⁷ from bladder is attached to umbilical region of anterior
- 98 abdominal wall
- 99
- 100 A colonoscopic report in search of origin revealed a firm
- 101 extra-luminal mass at lower rectum. On the basis of imaging
- and symptoms, provisional diagnosis of an adenocarcinoma of
- 103 colonic origin or a urachal neoplasm was done and patient

was operated within one month of presentation. Procedure 104 was grossly cystoscopy followed by cytoreductive surgery. A 105 cystic mass approaching from the supero-anterior region was 106 found to have adherence and involvement with the wall of the 107 bladder. Wide excision of the urachal cystic mass was done. A 108 few nodular deposits were seen in bilateral paracolic 109 peritoneum (Right>Left) evoking the need for bilateral 110 paracolic peritonectomy. Infra-colic omentectomy was done 111 as there were macroscopic omental deposits as well. It was 112 followed by bladder peritonectomy. Further intraoperative 113 observation revealed deposits in the form of tumour nodules 114 over the small bowel mesentery which were excised and 115 electro-dessicated. No other dissection of pelvic lymph node 116 basin was performed. Finally, 2 layered closure of the bladder 117 defect under general anaesthesia concluded the operative 118 procedure of approximately four hours. Estimated blood loss 119 was 450 ml which was managed by one unit of intraoperative 120 whole blood transfusion. Another unit was transfused next 121 morning. Low urine output and occasional moderate 122 hypotension were the post-operative complication which was 123 managed by adequate parenteral hydration only. The duration 124 of post-operative hospital stay was 5 days. Obtained specimen 125 of hypogastric mass with umbilicus and bladder wall along 126 with omentum and peritoneum was sent for histopathological 127 examination which opined for the existence of a tumour with 128 greatest dimension of 11cm, microscopic examination of 129 which showed mucinous adenocarcinoma of grade III with 130 invasion of the bladder wall [Figure 3,4]. 131

132



- Figure 3: Clusters of malignant cells floating in pools of
- ¹³⁵ mucin. Transitional epithelium of urinary bladder is also seen
- in adjacent areas (low power view ;10x X 10; Haematoxylin
- 137 and Eosin)
- 138
- 139
- 140
- 141
- 142



143

Figure 4: Mucin secreting adenocarcinoma is confirmed (high
power view; 40x X 10; Haematoxylin and Eosin)


146

147 148

140

- 150 Though resected margins were negative, tumour deposits were
- 151 found in right para-colic peritoneum, left para-colic
- 152 peritoneum, omentum, bladder and pelvic peritoneum and
- ¹⁵³ mesenteric nodule obtained from small bowel resection. It
- established the pathological stage of the tumour to be IIIC.
- 155 Following immunohistochemistry (IHC) report was positive
- 156 for both Cytokeratin 7 and Cytokeratin 20. CDX2, CK 5/6 and
- anti-P63 was negative, which finally clinched the diagnosis of
- an urachal remnant tumour. Post-operative CECT scan was
- 159 performed after three weeks following surgery which revealed

- focal irregular thickening of urinary bladder pointing towardsthe residual tumour [Figure 5].



- ¹⁶⁶ irregular thickening of bladder wall

168	Hence, adjuvant chemotherapy was planned with cisplatin +
169	5FU regimen and patient received six cycles of the planned
170	chemotherapy. The time elapsed after surgery is about 18
171	months till the last follow up. Patient was asymptomatic
172	which established the disease free survival to be 11 months
173	following completion of 6th cycle of chemotherapy i.e. the
174	last day of active treatment.
175	
176	
177	
178	
179	
180	DISCUSSION
181	DISCUSSION
182	Urachal carcinoma is a rara antity as it constitutes 0.35 to
183	Urachal carcinoma is a rare entity as it constitutes 0.35 to 0.7 % of all bladder cancers and 22-35% of adenocarcinomas
184 185	taking place in bladder[1,2]. This devastating bladder
185	malignancy accounts for an estimated 0.01% of all adult
180	cancers [3].
187	Urachal cancer first described by Hue and Jacquin in 1863,
189	was reported after translation and summarization by Sheldon
190	[2]. Begg was the first who described the entity extensively in
191	1931[4].
192	Located in the space of Retzius, the urachus is a vestigial
193	musculofibrous band of tissue. It is covered anteriorly by the
194	fascia transversalis and posteriorly by the peritoneum [3]. The
195	allantois is connected to the foetal bladder by the urachal
196	canal during early phase of embryonic development [4].
197	Descend of the bladder takes place into the pelvis during the
198	4th month of fetal development. It is followed by the
199	stretching of the urachus which turns into the median
200	umbilical ligament, that joins the umbilicus to the dome of the

- bladder. If remnants of the allantois remain within the
- ligament, they may develop themselves into neoplasms.
- ²⁰³ Urachal remnants have been identified in the dome and
- anterior wall commonly and rarely in the posterior wall of the
- ²⁰⁵ bladder in one third of cases in post mortem studies.[5]
- 206
- 207 The urachus has intramucosal, intramuscular and supravesical
- segments. It contains three distinct tissue layers:1) an
- 209 epithelial canal lined by urothelium, 2) submucosal
- connective tissues and 3) an outer layer of smooth muscle. As
- urachal cyst or neoplasms can originate from any of these
- layers, it can be either epithelial or mesenchymal[5].
- 213
- Though adenocarcinomas of the bladder have a relatively
- higher incidence in women as compared to urothelial
- carcinomas, urachal carcinomas have been reported at a
- higher incidence in men [6,7].
- 218
- 219 Dome-based urachal remnant neoplasms occupies the
- majority of tumors [8,9]. Urachal remnants have been
- observed in the midline or vertex in 54% and in the anterior
- wall in 2% of patients. Schubert, Pavkovic and Bethke-
- Bedurftig have also demonstrated it the posterior wall in 14%
- 224 [5].
- 225
- With mean survival between 12 and 24 months for a locally
- advanced or metastatic disease, and with a 5-year survival rate
- of only 43% urachal carcinoma establishes itself as a
- devastating disease [10,11]. By dint of late presentation of
- symptoms, early local invasion and propensity for distal
- 231 metastasis urachal cancer concludes with a poor
- prognosis[12]. If and when bladder invasion takes place,

irritative voiding, mucous-like discharge, and haematuria like

common urologic symptoms are presented [13].

235

MD Anderson Cancer Centre (MDACC) has fixed the

- 237 diagnostic criteria for urachal remnant tumour including
- 238 2 main and 4 supportive criteria [14]. The main criteria are: 1)
- midline location of the tumour and 2) a sharp demarcation
- between the tumour and normal surface epithelium [13].
- 241 Supportive criteria include: a) an enteric histology, b) the
- absence of urothelial dysplasia, c) the absence of cystitis
- cystica and d) the absence of a primary adenocarcinoma of
- another origin [11,13].
- 245

246 Though investigation procedure often starts with an

²⁴⁷ ultrasonography (USG) of whole abdomen, standard imaging

- work up including Computed Tomography (CT) Scan and/or
- 249 Magnetic Resonance Imaging (MRI) Scan of abdomen and
- 250 pelvis are the major imaging modalities to proceed towards
- diagnosis. Heterogeneity and calcification in a soft tissue
- mass is the general appearance of urachal remnant tumour in
- 253 USG, while local staging and evaluation of distant metastasis
- are performed with imaging weapons like CT scan and/or
- ²⁵⁵ MRI scan. Mixed solid and cystic tumors are demonstrated in
- ²⁵⁶ 84% of cases of urachal tumour on CT scan [15], others
- appear solid. The visible cystic component is mucin. CT scan
- also reveals peripheral calcification, which is another

remarkable feature [16].

260

In 88% of the cases the tumour bulk is seen outside the lumen

of the bladder. On MRI, sagittal images are very important as

- they define the location of the tumour in details . On T2
- sequence, focal areas of high intensity signify mucinous
- 265 component, highly suggestive of adenocarcinoma. Whereas

- the solid component is isointense to soft tissue on T1, and
- shows enhancement with contrast. For confirmation of
- diagnosis cystoscopy along with cystoscopic biopsy is
- performed [16]. Primary and secondary adenocarcinomas are
- 270 differentiated with the help of immunohistochemistry (IHC).
- 271 IHC positivity for both CK7 and CK20 coins the diagnosis of
- 272 primary adenocarcinomas of the bladder, while only CK20 is
- expressed in colonic adenocarcinomas [17].
- 274
- 275
- ²⁷⁶ Three different staging systems of urachal cancer have been
- proposed, although they are yet to be validated: Sheldon,
- 278 Mayo, and Ontario staging systems. Sheldon et al [2]
- 279 proposed a staging system involving localization of the
- tumour (Table 1).
- 281
- Table 1
- The urachal cancer staging system as defined by Sheldon et al
- 284 in 1984.

IIIA

IIIB

IIIC

Stage <u>Definition</u>

- Stage I Urachal cancer confined to urachal mucosa
- Stage II Urachal cancer with invasion confined to urachus itself
- Stage Local urachal cancer extension to bladder
- Stage Local urachal cancer extension to abdominal wall
- Stage Local urachal cancer extension to peritoneum
- StageLocal urachal cancer extension to viscera otherIIIDthan bladder

<u>Stage</u>	Definition
Stage IVA	Metastatic urachal cancer to lymph nodes
Stage IVB	Metastatic urachal cancer to distant sites
	1
classifica	ario staging system is yet another simplified ation of urachal tumour involving 4 stages: confined as (T1), confined to bladder (T2), invading

- surrounding fat (T3), and extending to the peritoneum (T4)[19].
- 291 292

285 286 287

288 289

- ²⁹³ The gold standard surgical approach for the management of
- localized urachal cancer is an excision of the urachus,
- umbilicus, and partial cystectomy combined with bilateral
- 296 pelvic lymphadenectomy. One of the most significant
- predictors of urachal cancer prognosis is surgical margin
 status [18].
- 299
- 300 The choice of regimens has been based largely on case reports
- and single institution experiences. Tried regimens are depicted
- 302 in List1[20].
- 303
- 304
- ³⁰⁵ List 1. Chemotherapy regimens tested in urachal cancers

Regimen

S-1+cisplatin ×5 courses S-1+cisplatin

FOLFOX4

Regimen Irinotecan IFL Cisplatin+paclitaxel+ifosfamide 5-FU+doxorubicin+VP16,doxorubicin+mitomycin-C+cisplatin Doxorubicin+mitomycin-C+ cisplatin, uracil/ftorafur 5-FU+doxorubicin+mitomycin-C Methotrexate+5-FU+epirubicin+cisplatin Ifosphamide+5-FU+VP16+cisplatin Cisplatin+5-FU MVAC

Taxol+methotrexate+cisplatin

Gem-FLP

- 306 S-1: oral fluoropyrimidine; FOLFOX4: oxaliplatin 85 mg/m2
- 307 (D1), leucovorin 200 mg/m2 (D1,2), fluoruracil 400 mg/m2
- 308 (D1, D2), fluorouracil 600 mg/m2 CIV over 22 hours (D1,2);
- IFL: irinotecan 125 mg/m2, 5FU 500mg/m2, leucovorin
- 310 20mg/m2, once weekly for 4 to 6 weeks; MVAC:
- methotrexate, vinblastine, adriamycin, cisplatin; Gem-FLP:
- 312 gemcitabine, 5FU, leucovorin, cisplatin.
- 313

314 CONCLUSION

- 315 Imaging modalities, even histopathological examination may
- not suffice to distinguish between urachal adenocarcinoma
- and adenocarcinoma colon, so immunohistochemistry remains
- as the mandatory tool to determine the diagnosis. Late

- presentation of symptoms, early local invasion and propensity
- 320 for distal metastasis make urachal remnant carcinoma a
- devastating disease for which surgery may not be adequate
- always and should be followed by adjuvant chemotherapy to
- 323 proceed towards a favourable outcome.
- 324

325 CONSENT

- 326 All authors declare that written informed consent was
- 327 obtained from the patient (or other approved parties) for
- ³²⁸ publication of this paper and accompanying images.

329

330 ETHICAL APPROVAL

- All authors hereby declare that all experiments have been
- examined and approved by the appropriate ethics committee
- and have therefore been performed in accordance with the
- ethical standards laid down in the 1964 Declaration of

335 Helsinki.

- 336 COMPETING INTERESTS
- 337 Authors have declared that no competing interests exist.

338339 REFERENCE

- 340
- Reuter V., The urothelial tract: renal pelvis, ureter, urinary
 bladder and urethra. Lippincott Williams and Wilkins;
 Philadelphia.
- 344
 345
 346
 347
 348
 348
 349
 349
 349
 349
 340
 341
 341
 341
 342
 343
 344
 345
 345
 345
 345
 345
 345
 346
 347
 347
 348
 348
 348
 349
 349
 349
 349
 349
 349
 341
 341
 341
 345
 345
 345
 345
 345
 345
 345
 345
 345
 345
 346
 347
 347
 347
 348
 348
 348
 348
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
 349
- Scabini S., Rimini E., Romairone E., Scordamaglia R.,
 Vallarino L., Giasotto V. Urachal tumour: case report of a
 poorly understood carcinoma. World J Surg Oncol. 2009;7:82.

349	4. Begg RC. The Urachus: its Anatomy, Histology and
350	Development. J Anat. 1930;64:170–183.
351	5. Schubert G.E., Pavkovic M.B., Bethke-Bedurftig B.A.
352	Tubular urachal remnants in adult bladders. J
353	Urol. 1982;127(1):40–42.
354	6. Johnson DE, Hodge GB, Abdul-Karim FW, et al. Urachal
355	carcinoma. Urology. 1985;26:218–221.
356	7. Kakizoe T, Matsumoto K, Andoh M, et al.
357	Adenocarcinoma of urachus. Report of 7 cases and review of
358	literature. Urology. 1983;21:360–366.
359	8. Johnson DE, Hodge GB, Abdul-Karim FW, et al. Urachal
360	carcinoma. Urology. 1985;26:218–221.
361	9. Mostofi FK, Thomson RV, Dean AL., Jr Mucous
362	adenocarcinoma of the urinary bladder. Cancer. 1955;8:741–
363	758.
364	10. Molina J.R., Quevedo J.F., Furth A.F., Richardson R.L.,
365	Zincke H., Burch P.A. Predictors of survival from urachal
366	cancer: a Mayo Clinic study of 49
367	cases. Cancer. 2007;110(11):2434–2440.
368	11. Siefker-Radtke A.O., Gee J., Shen Y., Wen S., Daliani D.,
369	Millikan R.E. Multimodality management of urachal carcinoma:
370	the M. D. Anderson Cancer Center experience. J
371	Urol. 2003;169(4):1295–1298.
372	12. Ashley R.A., Inman B.A., Sebo T.J., Leibovich B.C.,
373	Blute M.L., Kwon E.D. Urachal carcinoma: clinicopathologic
374	features and long-term outcomes of an aggressive
375	malignancy. Cancer. 2006;107(4):712–720.
376	13. Siefker-Radtke A. Urachal carcinoma: surgical and
377	chemotherapeutic options. Expert Rev Anticancer
378	Ther. 2006;6(12):1715–1721.
379	14. Gopalan A., Sharp D.S., Fine S.W., Tickoo S.K., Herr
380	H.W., Reuter V.E. Urachal carcinoma: a clinicopathologic
381	analysis of 24 cases with outcome correlation. Am J Surg
382	Pathol. 2009;33(5):659–668.
383	15. Wong-You–Cheong J.J., Woodward P.J., Manning M.A.,
384	Sesterhenn I.A. Neoplasms of the urinary bladder: radiologic-
385	pathologic correlation. Radiographics. 2006;26(2):553–580.

386	16. Ashley R.A., Inman B.A., Sebo T.J., Leibovich B.C.,
387	Blute M.L., Kwon E.D. Urachal carcinoma: clinicopathologic
388	features and long-term outcomes of an aggressive
389	malignancy. Cancer. 2006;107(4):712–720.
390	17. Singh I., Prasad R. Primary urachal mucinous
391	adenocarcinoma of the urinary bladder. J Clin Diagn
392	Res. 2013;7(5):911–913.
393	18. Pinthus J.H., Haddad R., Trachtenberg J., Holowaty E.,
394	Bowler J., Herzenberg A.M. Population based survival data on
395	urachal tumors. J Urol. 2006;175(6):2042–2047. discussion 7
396	19. Herr H.W., Bochner B.H., Sharp D., Dalbagni G., Reuter
397	V.E. Urachal carcinoma: contemporary surgical outcomes. J
398	Urol. 2007;178(1):74–78. discussion 8.
399	20. Elser C, Sweet J, Cheran SK, Haider MA, Jewett M, Sridhar
400	SS. A case of metastatic urachal adenocarcinoma treated with
401	several different chemotherapeutic regimens. Can Urol Assoc
402	J. 2012;6:E27–31.